Jefferies analyst Roger Song raised the firm’s price target on aTyr Pharma (ATYR) to $17 from $9 and keeps a Buy rating on the shares. Efzofitimod showed encouraging Phase 1/2 trials as clinical proof-of-concept for pulmonary sarcoidosis, with the Phase 3 having more stringent tapering which could further diverge the delta for steroid reduction, the analyst tells investors in a research note. The firm said its analysts suggests roughly 60% POS hitting statistical significance, with about 37% POS showing 3mg+ delta, driving a positive skewed stock move and supporting potential first approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Optimistic Buy Rating for aTyr Pharma Amid Promising EFZO-FIT Trial Prospects
- Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study
- Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach
- Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma
- aTyr Pharma: Strong Financials and Promising Therapeutic Candidate Drive Buy Rating